ClinicalTrials.gg
CompletedNCT00630929Updated Feb 21, 2021

Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)

A Phase 4 interventional study of Ibuprofen and Placebo in Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 33 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing celecoxib in Osteoarthritis, Knee — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis, Knee.

Enrollment
4th of 14
388 · median 216
Started
2003
with 2 others
Phase 4
10 of 14
1 open now
Registered
6th of 14
by date
Lead sponsor
6 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing celecoxib in Osteoarthritis, Knee, this one is the 4th largest by enrollment, is one of 3 that started in 2003, is one of 10 in phase 4, and was the 6th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria:

  • Aged >=40 years old
  • Diagnosed with OA of the knee according to the American College of Rheumatology and OA in flare state at baseline visit
  • Functional capacity class of I-III

Exclusion Criteria:

Exclusion criteria:

  • Inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
  • Acute joint trauma at index joint within the past 3 months with active symptoms
  • Score of >=20 on PHQ-9 or score of >=1 on PHQ-9 item i
  • Use of mobility assisting device for \<6 weeks or use of walker
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
388 participants (actual)

Study arms

  • Active comparator
    A

    Drug: Ibuprofen

  • Placebo comparator
    C

    Drug: Placebo

  • Experimental
    B

    Drug: Celecoxib

Interventions

  • 800 mg oral tablet 3 times daily with meals for 6 weeks

  • DrugPlacebo

    Matched placebo orally for 6 weeks

  • 200 mg oral capsule once daily with morning meal for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in patient's assessment of arthritis pain according to visual analogue scale

    Time frame: Week 6

Secondary outcomes

  1. Change from baseline in American Pain Society Modified Brief Pain Inventory Short Form pain scores

    Time frame: Days 1-7

  2. Change from baseline in patient's assessment of arthritis pain according to visual analogue scale

    Time frame: Week 2

  3. Change from baseline in patient and physician global assessments of arthritis

    Time frame: Weeks 2 and 6

  4. Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index

    Time frame: Week 6

  5. The Pain Satisfaction Scale

    Time frame: Week 6

  6. The Patient Health Questionnaire (PHQ-9)

    Time frame: Week 6

  7. Measurement of upper gastrointestinal tolerability

    Time frame: Weeks 2 and 6

  8. Adverse events

    Time frame: Weeks 2 and 6

  9. Laboratory test results

    Time frame: Week 6

  10. Vital signs

    Time frame: Weeks 2 and 6

  11. Physical examination

    Time frame: Week 6

07

Study locations

33 sites
  • Pfizer Investigational Site
    Bad Muender, 31848, Germany
  • Pfizer Investigational Site
    Beckum, 59269, Germany
  • Pfizer Investigational Site
    Berlin, 10435, Germany
  • Pfizer Investigational Site
    Berlin, 10559, Germany
  • Pfizer Investigational Site
    Berlin, 12687, Germany
  • Pfizer Investigational Site
    Berlin, 13125, Germany
  • Pfizer Investigational Site
    Ostseebad Damp, 24351, Germany
  • Pfizer Investigational Site
    Schwerin, 19057, Germany
  • Pfizer Investigational Site
    Stade, 21680, Germany
  • Pfizer Investigational Site
    Tostedt, 21255, Germany
  • Pfizer Investigational Site
    Weener, 26826, Germany
  • Pfizer Investigational Site
    Barcelona, 08029, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Cadiz, 11009, Spain
  • Pfizer Investigational Site
    Guadalajara, 19002, Spain
  • Pfizer Investigational Site
    Madrid, 28035, Spain
  • Pfizer Investigational Site
    Madrid, 28040, Spain
  • Pfizer Investigational Site
    Madrid, 28046, Spain
  • Pfizer Investigational Site
    Oviedo, 33006, Spain
  • Pfizer Investigational Site
    Sevilla, 41014, Spain
  • Pfizer Investigational Site
    Valencia, 46009, Spain
  • Pfizer Investigational Site
    Chelmsly WOOD, Birmingham B37 7TR, United Kingdom
  • Pfizer Investigational Site
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Pfizer Investigational Site
    Chorley, Lancs PR7 1NY, United Kingdom
  • Pfizer Investigational Site
    Liverpool, Lancs L1 9AD, United Kingdom
  • Pfizer Investigational Site
    Cannock, Mid Staffordshire WS11 2XY, United Kingdom
  • Pfizer Investigational Site
    Addlestone, Surrey KT15 2BH, United Kingdom
  • Pfizer Investigational Site
    Huddersfield, HD3 3EA, United Kingdom
  • Pfizer Investigational Site
    London, NW3 2PF, United Kingdom
  • Pfizer Investigational Site
    London, SE5 9RS, United Kingdom
  • Pfizer Investigational Site
    Manchester, M41 5SL, United Kingdom
  • Pfizer Investigational Site
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • Pfizer Investigational Site
    Wigan, WN6 9EW, United Kingdom
08

References and documents

Publications

  • Gordo AC, Walker C, Armada B, Zhou D. Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial. J Int Med Res. 2017 Feb;45(1):59-74. doi: 10.1177/0300060516673707. Epub 2017 Jan 12. PubMed 28222627 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2008
First posted
Mar 7, 2008
Start
Jan 2003
CompletionActual
Feb 2004
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00630929
Responsible party
Sponsor
First posted
Mar 7, 2008
Start date
Jan 2003
Completion
Feb 2004
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion